Josef H. von Rickenbach, a director at Rein Therapeutics (NASDAQ:RNTX), recently purchased $49,560 worth of common stock through open market transactions in late May 2026.
He acquired 47,060 shares between May 21 and May 27, at weighted average prices ranging from $1.0422 to $1.0708 per share.
Details: 3,420 shares on May 21, 15,950 on May 22, 23,190 on May 26, and 4,500 on May 27. He now holds 62,514 shares directly.
The stock trades at $1.11, market cap $104 million. Bond.az analysis suggests it is overvalued with a weak financial health score.
Recent news: Rein Therapeutics raised $57.5 million in an underwritten public offering and dosed the first patient in a Phase 2 trial for LTI-03, a treatment for idiopathic pulmonary fibrosis.
